FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

NCT05639543 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
67
Enrollment
INDUSTRY
Sponsor class

Stopped Intercept made the business decision to terminate the study on 31 Mar 2026 as there was no clear evidence of potential benefit of INT-787 in sAH. This decision was not based on a safety concern.

Conditions

Interventions

Sponsor

Intercept Pharmaceuticals